Novel Formazan Derivative: Synthesis, Characterization, Anti-breast Cancer and Antioxidant Investigation

New formazan (FOZ) derivative was synthesized and evaluated as an anti-breast cancer and antioxidant agent. Chemical structure of FOZ was proved by CHN, FT-IR, 1H-NMR and Mass techniques. The anti-proliferative activity of FOZ was estimated toward breast cancer cells. The synthesized compound displayed significant anti-breast cancer activity towered MCF-7 cells. The MTT examination demonstrated that 16 µg/ml of FOZ and doxorubicin (Dox) as a standard drug suppressed cell growth by 83.33% and 92.66%, respectively after 48hrs. The formazan antioxidant activity was estimated in vitro at various concentrations (25-400ug/ml) and the outcomes showed that 400 μg/ml of FOZ was more efficient compared to ascorbic acid